Innoviva, Inc.
INVA
Jodie situation report
Innoviva, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 10 directly disclosed connections are confirming.
- INVA's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if INVA's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind INVA
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ARMPFiling-linked nameinvesteeMay 6, 2026 ▾
“In addition, we own other strategic healthcare assets, such as a significant stake in Armata Pharmaceuticals, Inc.”
EGEverest Group, Ltd.supplierNov 5, 2025 ▾
“La Jolla also entered into the Everest commercial supply agreement (the “Everest Supply Agreement”) whereby La Jolla will supply Everest a minimum quantity of XERAVA ® and will transfer to Everest certain XERAVA ® -related manufacturing know-how.”
Depended on by
ZLABZai Lab LimitedinvesteeFeb 26, 2026 ▾
“We have an exclusive license from Entasis (now a wholly owned subsidiary of Innoviva) to develop and commercialize SUL-DUR in Asia Pacific.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 11 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
INVA is currently a Leader in the organic co-movement group Bacterial Infection Treatments. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for INVA; it is not active in the latest market snapshot.